Reuters: Regulatory News: Watson seeks approval of generic version of cancer drug Velcade

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Watson seeks approval of generic version of cancer drug Velcade Dec 28th 2012, 15:46 Fri Dec 28, 2012 10:46am EST Dec 28 (Reuters) - Watson Pharmaceuticals Inc said on Friday it has applied for U.S. approval to market a generic version of Velcade, a treatment for multiple myeloma made by Takeda Pharmaceutical Co. Takeda's Millennium unit filed a lawsuit last week against Watson's Actavis unit, seeking to prevent Actavis from selling generic Velcade prior to the expiration of certain U.S. patents. Drug companies that file lawsuits against generic manufacturers which challenge their patents are typically granted a protection period of up to 30 months from the date of the generic drugmaker's filing for approval of its own drug. Velcade, which generated sales of $740 million in the 12 months ended October, is one of the leading treatments for multiple myeloma.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions